• Feb 27, 2025

Elastic (NYSE:ESTC) Beats Q4 Sales Targets, Stock Jumps 17.5%

Search software company Elastic (NYSE:ESTC) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 16.5% year on year to $382.1 million. Guidance for next quarter’s revenue was better than expected at $380 million at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $0.63 per share was 34.4% above analysts’ consensus estimates.

  • Feb 27, 2025

WeightWatchers (NASDAQ:WW) Beats Q4 Sales Targets

Personal wellness company WeightWatchers (NASDAQ:WW) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 10.5% year on year to $184.4 million. Its non-GAAP profit of $0.32 per share was significantly above analysts’ consensus estimates.

  • Feb 27, 2025

Fed’s Hammack Says Rates on Hold, Not Meaningfully Restrictive

(Bloomberg) -- Federal Reserve Bank of Cleveland President Beth Hammack said interest rates are not “meaningfully restrictive” and should be held steady for some time as officials wait for evidence inflation is returning to their 2% target. Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC’s Congestion Pricing Pulls In $48.6 Milli

  • Feb 27, 2025

Progyny (NASDAQ:PGNY) Posts Better-Than-Expected Sales In Q4, Stock Jumps 14.7%

Fertility benefits company Progyny (NASDAQ:PGNY) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.6% year on year to $298.4 million. On top of that, next quarter’s revenue guidance ($309 million at the midpoint) was surprisingly good and 10.3% above what analysts were expecting. Its non-GAAP profit of $0.42 per share was 13.5% above analysts’ consensus estimates.

  • Feb 27, 2025

Alignment Healthcare (NASDAQ:ALHC) Reports Bullish Q4, Stock Soars

Health insurance company Alignment Healthcare (NASDAQ:ALHC) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 50.7% year on year to $701.2 million. On top of that, next quarter’s revenue guidance ($887.5 million at the midpoint) was surprisingly good and 4.1% above what analysts were expecting. Its GAAP loss of $0.16 per share was 11% above analysts’ consensus estimates.